Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2006;332:1106-1107 (13 May), doi:10.1136/bmj.332.7550.1106
It would be a shame if unresolved ethical dilemmas hampered this breakthrough
| The first 150 words of the full text of this article appear below. |
In June 2006 the US Food and Drug Administration is expected to approve a human papilloma virus (HPV) vaccine which is over 90% effective in preventing new infections and precancerous cervical lesions caused by the HPV types that it covers.1 2 The vaccine prevents cancer through preventing sexual transmission of HPV types that cause cervical cancer.3 This link to a sexually transmitted infection raises ethical concerns that must be resolved if the benefits of preventing cancer are to be realised.
The vaccine must be given before HPV infection is acquired. It is most likely to be recommended for 11-12 year olds, because by the ninth grade (age 14-15) 28% of girls in the US are sexually active. This has prompted some advocates of premarital abstinence to charge that HPV vaccination will condone or promote sexual promiscuity. However, its impact will probably be small because multiple factors are associated with initiation
Bernard Lo, professor of medicine
Program in Medical Ethics, Division of General Internal Medicine, and Center for AIDS Prevention Studies, University of California, San Francisco, USA
(bernie@medicine.ucsf.edu)
Read all Rapid Responses
What can you learn from this BMJ paper? Read Leanne Tite's Paper+